

ecto⁺
care[®]

because we care



Trusted by millions worldwide: Your brand for high quality consumer healthcare and beauty products.



www.ectocare.de

Medical Devices and Cosmetics with clinically proven efficacy based on medEctoIn[®].

Products – Available now

PRODUCT	REGULATORY CLASS IN EU
Atopic Dermatitis Cream 7%	IIa (MDD)
Psoriasis Cream 5%	IIa (MDD)
Basic Cream 3.5%	Cosmetic
Moisture & Protection Eye Drops 0.5%	IIa (MDD)
Day & Night Intensive Eye Gel 2%	IIa (MDD)
Allergy Eye Drops 2%	IIa (MDD)
Allergy Nasal Spray 2%	IIb (MDR)
Allergy & Inflammation Inhalation Solution 1.3%	IIa (MDD)
Multi-Action Serum 2%	Cosmetic
Multi-Action Eye Cream 2%	Cosmetic
Hand Cream 0.5%	Cosmetic



Products – Available soon

PRODUCT	REGULATORY CLASS IN EU
Rhinitis Nasal Spray 2%	IIb (MDR)
Cough & Sore Throat Spray 2%	IIb (MDR)
Cough & Sore Throat Lozenges 0.6%	IIa (MDD)
Hypertonic Inhalation Solution 0.6%	IIb (MDR)
Inflammation Eye Drops 2%	IIb (MDR)
Intensive Care Vaginal Gel 2%	IIb (MDR)
Scalp Tonic 2%	Cosmetic
Basic Cream Face 4%	Cosmetic
SPF 50 Fluid 2%	Cosmetic





I want a world where people with atopic dermatitis, asthma, and allergies are no longer left to fend for themselves. Doctors often have little time, pharmacies only recommend standard products – and many sufferers feel helpless.

With ectocare®, I wanted to create a brand that helps those people. Real help, without compromise.

This is just the beginning. And I would be delighted if you would join us on this journey.

Eva Galik
Founder of ectocare®

What is ectocare®?

Developed by bitop, ectocare® is a high-quality OTC brand built on the science of medEctoin®. Our portfolio includes innovative medical devices and cosmetic products in diverse application forms: eye drops, nasal and throat sprays, creams and gels, inhalation solutions, and lozenges and mouthwash. These provide effective treatment and prevention across key therapeutic areas: Dermatology, Cough & Cold, Allergy, Respiratory Health, Eye Care, and Intimate Care.



Why partner with us?



Clinically proven efficacy



Safe for long-term use



Market-ready – including artwork, registrations & compliance



High consumer acceptance – over 65 million medEctoin® products sold worldwide



Wide range – Dermatology, Cough & Cold, Allergy, Respiratory Health, Eye Care, and Intimate Care



EU GMP manufacturing & ISO 13485 quality system

How to become a distributor?

Step 1
Select the right products for your market.

Step 2
Show your vision and present your business case – we'll review it together.

Step 3
Once approved, you become part of the ectocare® partner network.

Step 4
We support you with marketing content, artwork, and regulatory approvals.

Step 5
Launch confidently with our ongoing support.

We handle compliance, artwork, and registrations – so you can focus on growing your business with **globally trusted, clinically proven** products.

Indications



Allergy




Dermatology



Cough & Cold



Eye Care




Airway Diseases




Female Health

Application Forms



Eye Drops



Nasal and Throat Sprays



Creams and Gels



Inhalation Solution



Lozenges



Mouthwash

Quality and Safety at ectocare®


At ectocare®, quality is our top priority. We implemented a robust, cross-departmental quality management system that meets international standards, guaranteeing both safety and reliability in every product—trusted by partners worldwide.

In-House Excellence: Ingredient Integrity

As a pioneer in highly effective medical devices and cosmetics, ectocare® makes sure that each product only contains the purest and best medEctoin®:

Purity Testing: medEctoin® undergoes cutting-edge analytical testing to ensure it meets exact purity specifications and is free from contaminants.

Batch Release Testing: Every production batch is comprehensively tested for stability, efficacy, and safety before release to the market.



Finished Product Assurance

For medEctoin®-based medical devices and finished products, ectocare® ensures uncompromised quality through:

Rigorous CMO Qualification: Partnering only with Contract Manufacturing Organizations in Germany and Europe that are ISO 13485-certified and regularly audited for compliance.

In-Process Quality Controls: Continuous monitoring by CMOs throughout production to uphold regulatory and bitop's internal standards.

Final Inspection by bitop: Each completed product undergoes thorough scrutiny—including checks for sterility, microbial safety, accurate packaging and labeling, and overall conformity to specifications under ISO 13485.



Atopic Dermatitis Cream 7%



Packaging:

Aluminum Tube (50 ml)

Regulatory status in Europe:

Medical device class: IIa (MDD)

Intended Use:

Cream for the treatment and prevention of atopic dermatitis and extremely dry skin

Claims:

71% less itching – noticeable relief for your skin

Up to 50% fewer atopic dermatitis symptoms – visibly soothed skin

+61% more moisture in just 1 hour – feel instantly more comfortable

Repairs the damaged skin barrier by improving hydration and cell stabilization

Reduces inflammatory skin reactions and soothes irritated, damaged skin

Free from steroids

Target Group:

Infants (1+ months), children, and adults



Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Dermatitis Cream 7%	N = 65 Comparator- controlled, double- blind, multicenter clinical study	Up to 50% improvement of atopic dermatitis symptoms. SCORAD: Superior performance over active comparator.	Marini et al. 2014
medEctoin® Dermatitis Cream 7%	N = 30 Prospective, observational, single- arm clinical study	Significant improvement of atopic dermatitis severity and quality of life over 4 weeks.	Hon et al. 2019
medEctoin® Dermatitis Cream 7%	N = 50 Open- label, controlled, prospective stud	Significant reduction of atopic dermatitis symptoms in children using medEctoin® Cream as part of a comprehensive treatment regimen.	Kudryavtseva et al. 2019

Improvement of Atopic Dermatitis




Figure 1:

Improvement of Atopic Dermatitis symptoms by up to 50%.

Reference:

Marini et al. 2014.

Psoriasis Cream 5%



Packaging:

Aluminum Tube (50 ml)

Regulatory status in Europe:

Medical device class: IIa (MDD)

Intended Use:

Cream for the treatment and prevention of psoriasis

Claims:

79% less flaking, redness, itching, and dryness – noticeably smoother skin

Strengthens the skin barrier and moisturizes – protects against further dryness

Supports the natural exfoliation of dead skin cells – reduces plaque and roughness

Contributes to the normalization of skin cell production

Reduces skin inflammation and supports the skin's natural regeneration process

Provides intensive moisture and prevents further dryness

Target Group:

Infants (1+ months), children, and adults with psoriasis



Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Psoriasis Cream	N = 94 Prospective, observational clinical study	Significant improvement of Psoriasis symptoms by 79%. 82% of patients rated the tolerability as very good or good.	Vestweber 2009
medEctoin® Psoriasis Cream	N = 101 Prospective, observational clinical study	Significant improvement of Atopic dermatitis symptoms: Erythema, Hardening of the skin, Pruritus, Dryness and Desquamation.	Clinical study report btph-005-2008
Dermaveel® (5.5% medEctoin®)	N = 242 Prospective, observational clinical study	Significant reduction of pruritus and sleep disorder. Very good safety profile. SCORAD reduction of 64.3%.	Wilkowska et al. 2015

Improvement rate of Psoriasis symptoms




Figure 1:
Improvement of psoriasis symptoms after 4 and 8 weeks.

Reference:
Vestweber 2009.

Basic Cream 3.5%



Intended Use:

Daily care for itchy, red and extremely dry skin

Claims:

Intensive moisturization for up to 7 days

Dermatologically tested on atopic skin and rated as very good

Helps to relieve itching, stinging, and burning sensations of the skin

Supports the stabilization of the skin barrier between acute flare-ups of atopic dermatitis and psoriasis

Reduces skin irritation and soothes allergic skin

Packaging:

Plastic tube (200 ml)

Regulatory status in Europe:

Cosmetic product

Target Group:

Infants (1+ months), children, and adults with very dry and sensitive skin



Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
4% medEctoin® Cream 0.25% Hydrocortisone Cream	N = 20 Observational, prospective, comparator-controlled clinical study	4% medEctoin® Cream outperforms 0.25% Hydrocortisone Cream in reducing trans-epidermal water loss and skin redness.	Prieur and Nissen 2004
0.5% medEctoin® Cream 1% medEctoin® Cream	N = 5 Prospective, placebo controlled clinical study	0.5% and 1% Ectoin® natural improve skin hydration by 30% within 12 days 1% Ectoin® natural maintains the skin hydration level for up to 7 days (without reapplication)	Graf et al. 2008

Long-term Moisturization




Figure 1:
Long-term moisturization with 0.5 % and 1 % Ectoin® creams

Reference:
Graf et al. 2008

Multi-Action Serum 2%



Packaging:

Airless dispenser:
Serum – 30 ml / Eye Cream – 15 ml

Regulatory status in Europe:

Cosmetic product

Intended Use:

Gentle facial care for very sensitive skin

Claims:

Reduces rough skin by up to 86%

Provides long-lasting hydration for up to 7 days

Reduces fine lines and wrinkles

Up to 72% less skin irritation

Absorbs quickly and is non-greasy

Noticeably soothes sensitive skin from the first application

Supports the natural skin microbiome

Target Group:

Adults with sensitive and very dry skin

Multi-Action Eye Cream 2%



Packaging:

Airless dispenser:
Serum – 30 ml / Eye Cream – 15 ml

Regulatory status in Europe:

Cosmetic product

Intended Use:

Intensive care for the sensitive eye area

Claims:

Instantly soothes irritated, dry and tired eyelids
+170% cell activity

Protects against environmental influences and helps the skin to stabilize itself

Provides up to 49% more hydration for the sensitive eye area

Reduces fine lines and wrinkles

Target Group:

Adults with sensitive and very dry skin

Hand Cream 0.5%



Intended Use:

Immediate relief for very dry, stressed, or cracked hands

Claims:

Soothes the skin from the first application – reduces skin irritation by up to 72%

Strengthens the skin barrier with proven effectiveness for up to 48 hours

Boosts the effect of your SPF – for effective protection against light-induced skin aging

Packaging:

Plastic tube (50 ml)

Target Group:

Adults with sensitive and very dry skin

Regulatory status in Europe:

Cosmetic product



Moisture & Protection Eye Drops 0.5%



Intended Use:

Eye drops for the treatment of dry, itchy and burning eyes

Claims:

Relieves burning, itching, and dryness of the eyes

Provides hydration through the combination of medEctoin® and hyaluronic acid and protects against further dryness

Reduces inflammation of dry or irritated eyes

Improves cell regeneration

Suitable for daily and preventive use

Packaging:

Dropper bottle (10 ml)

Regulatory status in Europe:

Medical device class: IIa (MDD)

Target Group:

Adults and children, suitable for contact lens wearers and sensitive eyes



Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Sicca Eye Drops	N = 65 Non-interventional, comparator-controlled clinical trial	Significant improvement in Tear Break-Up Time within 4 weeks vs. baseline; non-inferior to HA eye drops	Clinical study report btph-032- 2012-BAT04
medEctoin® Sicca Eye Drops	N = 60 Clinical, observational, two arm study	Significant improvement in dry eye symptoms in postmenopausal women and glaucoma patients	Veselovska et al. 2015
medEctoin® Sicca Eye Drops	N = 24 Prospective, clinical, observational study	Significant improvement of dry eye symptoms in patients with contact lens-associated dry eye	Veselovska 2016

Decrease of dry eye symptoms




Figure 1:
Decrease of all dry-eye symptoms between visit 1 and visit 2
(formulation without HA).

Reference:
btph-032-2012-BAT04

Day & Night Intensive Eye Gel 2%



Packaging:

Dropper bottle (10 ml)

Regulatory status in Europe:

Medical device class: IIa (MDD)

Intended Use:

Eye gel for the treatment and prevention of dry, irritated, and inflamed eyes

Claims:

Provides intensive and long-lasting hydration for dry and irritated eyes

Reduces inflammation of the conjunctiva

Relieves burning, itching, and foreign body sensation in the eye

Forms a protective film on the eye to prevent irritation

Supports wound healing after eye surgeries or injuries

Ideal for day and night use

Target Group:

Adults and children with severely dry or irritated eyes, suitable for contact lens wearers and sensitive eyes



Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Sicca Eye Drops	N = 65 Non-interventional, comparator-controlled trial	Significant improvement in Tear Break-Up Time within 4 weeks vs. baseline; non-inferior to HA eye drops	Clinical study report btph-032- 2012-BAT04
medEctoin® Sicca Eye Drops	N = 60 Clinical, observational, two arm study	Significant improvement in dry eye symptoms in postmenopausal women and glaucoma patients	Veselovska et al. 2015
medEctoin® Allergy Eye Drops 2%	N = 50 Non-interventional, randomized, controlled study	Immediate relief within 30 seconds post-CPT exposure; 87% reduction in irritation after 30 minutes	Clinical study report btph-015- 2018-AAT04- EES09

Decrease of dry eye symptoms




Figure 1:
Decrease of all dry-eye symptoms
(formulation: medEctoin® Sicca Eye Drops)

Reference:
btph-032-2012-BAT04

Allergy Eye Drops 2%



Packaging:

Dropper bottle (10 ml)

Regulatory status in Europe:

Medical device class: IIa (MDD)

Intended Use:

Eye drops for the treatment and prevention of allergic conjunctivitis symptoms

Claims:

Rapid relief of allergy symptoms – within 30 seconds

Alleviates common allergy symptoms such as itching, tearing, and redness

Reduces allergen-induced inflammation of the eye

Medical device with comparable efficacy to the drug Azelastine*

Supports the regeneration process of irritated and sensitive conjunctiva

Protects against the harmful influences of allergens

Target Group:

Adults and children, suitable for contact lens wearers and sensitive eyes



Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEcto ⁱⁿ ® Allergy Eye Drops 2%	N = 46 Double-blind, randomized, placebo-controlled, cross-over study	Significant reduction in acute allergic conjunctivitis symptoms vs. placebo.	Salapatek et al. 2021
medEcto ⁱⁿ ® Allergy Eye Drops 2%	N = 43 Non-interventional, comparator-controlled study	Slightly superior efficacy compared to azelastine eye drops in alleviating local allergic eye symptoms.	Werkhäuser et al. 2014
medEcto ⁱⁿ ® Allergy Eye Drops 2%	N = 50 Non-interventional, randomized, controlled study	Immediate relief within 30 seconds post-CPT exposure; 87% reduction in irritation after 30 minutes.	Clinical study report btph-015-2018-AAT04-EES09

30 seconds: Improvement of irritation




Figure 1: Quick improvement of eye irritation within 30 seconds (patients' evaluation).

Reference: btph-015-2018-AAT04-EES09

Allergy Nasal Spray 2%



Packaging:

Spray bottle (20 ml)

Regulatory status in Europe:

Medical device class: IIb (MDR)

Intended Use:

Nasal spray for the treatment and prevention of allergic rhinitis symptoms

Claims:

Relieves allergic symptoms (itchy, runny, and blocked nose; sneezing)

Naturally cleans the nose from allergens and pollutants

Reduces allergen-induced inflammation of the nasal mucosa

No habituation effect

Also suitable for preventive use

Supports the regeneration of irritated nasal mucosa

Target Group:

Adults and children (+2 years)



Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoïn® Allergy Nasal Spray 2%	N = 46 Double-blind, randomized, placebo-controlled, cross-over study	Significant reduction of acute allergic symptoms, based on Total Nasal Symptom Score evaluation.	Salapatek et al. 2021
medEctoïn® Allergy Nasal Spray 2%	N = 43 Non-interventional, comparator-controlled study	Slightly superior efficacy compared to azelastine nasal spray in alleviating local allergic symptoms in the nose.	Werkhäuser et al. 2014
medEctoïn® Allergy Nasal Spray 2%	N = 50 Non-interventional, comparator-controlled, cross-over study	Superior and significant efficacy compared to cromoglicic acid nasal spray in alleviating local allergic symptoms in the nose.	Clinical study report btph-015-2018-AAT04-EES09

Reduction of allergic rhinitis symptoms




Figure 1:
Symptom relief of Single Nasal Scores

Reference:
Werkhäuser et al. 2014

Allergy & Inflammation Inhalation Solution 1.3%



Packaging:

Ampoules (20 x 2.5 ml)

Regulatory status in Europe:

Medical device class: IIa (MDD)

Intended Use:

Inhalation Solution for the symptomatic treatment of acute and chronic airway diseases

Claims:

Supportive treatment and prevention of bronchitis symptoms

Prevents symptoms of allergic reactions of the respiratory system while suffering from allergic asthma or house-dust allergy

Protects and moisturizes the mucosa of the airways

Prevents drying of the mucous membranes

Loosens thick mucus and facilitates expectoration

For administration with common nebulizers

Target Group:

Adults and children with inflammatory respiratory diseases and allergic or non-allergic asthma



Clinical Results

PRODUCT	STUDY DESIGN	MAIN RESULTS	REFERENCE
medEctoin® Inhalation Solution	N = 135 Prospective, controlled, observational, multicenter study	Significant reduction of bronchitis symptoms. Slightly superior improvement vs. saline solution.	Tran et al. 2019
medEctoin® Inhalation Solution	N = 18 Double-blind, randomized, placebo-controlled, crossover study	Significant improvement in lung function parameters. Best efficacy observed at 1.3% dose, including a decrease of exhaled nitric oxide.	Kappeler et al. 2011
medEctoin® Inhalation Solution	N = 36 Double-blind, randomized, placebo-controlled, crossover study.	Significant reduction of nitrogen oxides indicates reduced airway inflammation and potential improvement in respiratory symptoms.	Unfried et al. 2016

Baseline-adjusted symptoms scores





Figure 1: Improvement of bronchitis symptoms

Reference: Tran et al. 2019

The Science of medEctoin®

How it Works

medEctoin® is a **natural extremolyte** produced by microorganisms in extreme environments. It protects cells, membranes, and proteins from stress factors – helping to keep skin, eyes, and airways healthy.




medEctoin® surrounded by water molecules, forming the medEctoin® Hydro Complex.

Water Shell Formation (medEctoin® Hydro Complex):

medEctoin® forms a hydration shell around cells and biomolecules. This stabilizes moisture levels and strengthens the skin barrier.

Stabilization of Cells & Proteins

It protects cell membranes and proteins from oxidative stress, UV radiation, and allergens – keeping them structurally stable and functional.



Cross-section of the human cell surface with protective medEctoin® Hydro Complex.



Head groups of the lipid bilayer of the cell are stabilized by the medEctoin® Hydro Complex.

Anti-Inflammatory & Regenerative Effects

medEctoin® reduces the release of inflammatory mediators and supports the natural regeneration of skin and mucous membranes.

Real People, Real Stories

Because it Really Works

Our users share their experiences – authentic, honest, and inspiring. Millions of people worldwide already trust the power of medEctoIn®.

Anna Keller ✓



“My hands were extremely cracked, red, and painful from atopic dermatitis. I had tried countless creams without success. With ectocare®, the redness calmed down, the cracks started to heal, and my skin finally felt relieved. You can see the difference – it’s one of the few products that truly works.”



Michelle Braun ✓



For years, the skin on my neckline was constantly red and irritated. With ectocare®, the redness visibly reduced and the burning sensation eased. It’s the first product that truly brought me lasting comfort.

Sabine Vogt ✓



“My flare-ups caused intense itching and large inflamed patches. Since using ectocare®, the skin looks much calmer and the itching has eased significantly. The cream absorbs quickly without greasiness – and the results are clear.”



Let's Grow Together
Become a partner today

ecto⁺
care[®]

ectocare GmbH
Carlo-Schmid-Allee 5
DE-44263 Dortmund
info@ectocare.de
www.ectocare.de

